Stevanato Group (STVN) Q2 FY26 earnings call

Stevanato Group delivered solid Q2 FY26 results, driven by strong growth in Biopharmaceutical and Diagnostic Solutions and high-value solutions, particularly in biologics and GLP-1 therapies. The company completed the divestiture of Balda C. Brewer to optimize its footprint and focus on integrated drug delivery systems, highlighted by the European regulatory approval of its Alina variable dose pen platform. While the Engineering segment showed margin improvement, sales cycles remain elongated, and the company continues to invest heavily in capacity expansion in Fishers and Latina to support fu